Clinical Trials in Miami

Showing 6701-6720 of 11,431 trials

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

NCT01594957

This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of hepatic impairment to healthy subjects.

Hepatic Impairment

Novartis Pharmaceuticals53 participantsStarted Apr 2012

Miami, Florida, United States • Orlando, Florida, United States

COMPLETEDPhase 1< 1 mile

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

NCT02891408

The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic impairment.

Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences74 participantsStarted Sep 2016

Tustin, California, United States • Miami, Florida, United States • Orlando, Florida, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332

This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.

Type II Diabetes

Novartis Pharmaceuticals220 participantsStarted Mar 2012

Chula Vista, California, United States • Miami, Florida, United States • Orlando, Florida, United States +3 more locations

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Find Trials by Condition in Miami

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Dose Finding Study for QAW039 in Asthma

Helicobacter Pylori Genome Project (HpGP)

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Pharmacokinetics of rFVIIIFc at Two Vial Strengths